Reasons for immunologic inefficiency of antiretroviral therapy in patients with HIV

Cover Page

Cite item

Full Text

Abstract

The main component of the treatment of patients with HIV infection is highly active antiretroviral therapy (HAART), which can help to control the disease. The main goal of HAART is to increase the life duration and to maintain the quality of patients’ life. Improved survival among HIV-infected patients receiving highly active antiretroviral therapy is achieved mainly by a decrease of HIV RNA viral load, which increases CD4 lymphocytes count. However, some patients may present with discordant response to treatment, when there is no CD4 lymphocyte count elevation associated with the virus disappearing from the blood. Such patients retain immunodeficiency, despite long-term treatment. The risk of opportunistic infections on the background of insufficient immunological response, despite viral replication suppression, is higher than in patients with good immunological response to treatment. Consistently low CD4 cell counts are associated with an increased risk of AIDS diagnosis. Furthermore, this group of patients shows a slight increase in mortality not associated with AIDS-defining illnesses. The reasons for the low CD4 lymphocytes count increase in some patients achieving virologic response to HAART remain unclear. The immunological efficacy of treatment depends on many factors: baseline CD4 count, duration of HIV infection prior to HAART initiation, age, co-infection with HCV, presence of secondary diseases and comorbidities, HAART regimens, IL-2 use and others. Literature review covers the phenomenon of immunological «non-response» to HAART, factors leading to its development, and possible methods of correction. Currently, there are more questions than answers in the area of immunological non-effectiveness of HAART in HIV-infected patients.

About the authors

A F Oleynik

Republican Centre for AIDS and Infectious Diseases Treatment and Prevention, Kazan, Russia

V Kh Fazylov

Kazan State Medical University, Kazan, Russia

Email: vildan47@rambler.ru

References

  1. Бартлет Д., Галант Д., Фам П. Клинические аспекты ВИЧ-инфекции 2010. - М.: Р. Валент, 2010. - 490 с.
  2. Ладная Н.Н., Соколова Е.В., Юрин О.Г. и др. Развитие эпидемии ВИЧ-инфекции в регионах Российской Федерации в 2007 г. // Эпидемиол. и инфекц. болезни. - 2008. - №3. - С. 7-12.
  3. Покровский В.В. ВИЧ-инфекция. Информационный бюллетень №38, ФНМЦ БП СПИД. - М., 2013. - 52 с.
  4. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2009. - М.: Р. Валент, 2012. - 736 с.
  5. Antonello V.S., Appel-da-Silva M.C., Kliemann D.A. et al. Immune restoration in human immunodeficiency virus and hepatitis C virus coinfected patients after highly active antiretroviral therapy // Braz. J. Infect. Dis. - 2013. - Vol. 17, N 5. - P. 551-554.
  6. Blanco J.R., Jarrín I., Vallejo M. et al. Definition of advanced age in HIV infection: looking for an age cut-off // AIDS Res. Hum. Retroviruses. - 2012. - Vol. 28, N 9. - P. 1000-1006.
  7. Cingolani A., Cozzi Lepri A., Castagna A. et al. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition // Clin. Infect. Dis. - 2012. - Vol. 54, N 6. - P. 853-861.
  8. Daar E.S., Lynn H., Donfield S. et al. Hepatitis C virus load in associated with human immunodeficiency virus type 1 disease progression in hemophiliacs // J. Infect. Dis. - 2001. - Vol. 183. - P. 589-595.
  9. Deeks S.G., Barbour J.D., Grant R.M. Duration and predictors of CD4 T-cell gains in pations who continue combination therapy despite detectable plasma viremia // AIDS. - 2002. - Vol. 16. - P. 201-207.
  10. Dragsted U.B., Mocroft A., Vella S. et al. Predictors of immunological failure after initial respons to highly active antiretroviral therapy in HIV-1 infected adults: A EuroSIDA study // J. Infect. Dis. - 2004. - Vol. 190. - P. 148-155.
  11. Farías A.A., Kremer L.E., Allende L. et al. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection // Trans. R. Soc. Trop. Med. Hyg. - 2013. - Vol. 107, N 7. - P. 432-437.
  12. Focà E., Motta D., Pollara C. et al. Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy // New Microbiol. - 2012. - Vol. 2. - P. 227-231.
  13. Gilson R.J., Man S.L., Copas A. et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborativ HIV Cohort (UK CHIC) Study // HIV Med. - 2010. - Vol. 11. - P. 152-160.
  14. Goetz M.B., Boscardin W.J., Wiley D. et al. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning HAART // AIDS. - 2001. - Vol. 15. - P. 1576-1579.
  15. Grabar S., Kousignian I., Sobel A. et al. Immunological and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV // AIDS. - 2004. - Vol. 18. - P. 2029-2038.
  16. Grabar S., Le Moing V., Goujard C. et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of HAART // Ann. Intern. Med. - 2000. - Vol. 133. - P. 401-410.
  17. Hoover D.R. Would confirmatory retesting of CD4+ cells to verify AIDS status be too expensive? // J. Acquir. Immune Defic. Syndr. - 1993. - Vol. 6. - P. 537-539.
  18. Huttner A.C., Kaufmann G.R., Battegay M. et al. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy // AIDS. - 2007. - Vol. 21. - P. 939-946.
  19. Joly V., Fagard C., Grondin C. et al. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo) // Antimicrob. Agents Chemother. - 2013. - Vol. 57, N 2. - P. 758-765.
  20. Julg B., Poole D., Ghebremichael M. et al. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa // PLoSDuvivier C One. - 2012. - Vol. 7, N 2. - Р. 31161.
  21. Katlama C., Carcelain G., Duvivier C. et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despitehighly active antiretroviral therapy: the ILSTIM study - ANRS 082 // AIDS. - 2002. - Vol. 16, N 15. - P. 2027-2034.
  22. Kaufmann G.R., Furrer H., Ledergerber B. et al. Characteristics, determinants, and clinical relevans of CD4 T cell recovery to №500 cell/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy // Clin. Infect. Dis. - 2005. - Vol. 41. - P. 361-372.
  23. Kaufmann G.R., Perrin L., Pantaleo G. et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study // Arch. Intern. Med. - 2003. - Vol. 163. - P. 2187-2195.
  24. Kelley C.F., Kitchen C.M., Hunt P.W. et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment // Clin. Infect. Dis. - 2009. - Vol. 48. - P. 787-794.
  25. Kolte L., Dreves A.M., Ersboll A.K. et al. Association between larger thymic size and higher thymic output in HIV-infected patients receiving HAART // J. Infect. Dis. - 2002. - Vol. 185. - P. 1578-1585.
  26. Le Moing V., Thiebaut R., Chene G. et al. Predictors of long-term increase in CD(+) cell counts in HIV-infected patients receiving a protease inhibitor - containing antiretroviral regimen // J. Infect. Dis. - 2002. - Vol. 185. - P. 471-480.
  27. Ledergerber B., Egger M., Erard V. et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study // JAMA. - 1999. - Vol. 282. - P. 2220-2226.
  28. Ledergerber B., Landgren J.D., Walker A.S. et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure too all three antiretroviral-drug classes // Lancet. - 2004. - Vol. 364. - P. 51-62.
  29. Levy Y., Abrams D., Losso M.H. et al. Interleukin-2 therapy in patients with HIV infection // N. Engl. J. Med. - 2009. - Vol. 361, N 16. - P. 1548-1559.
  30. Lok J.J., Bosch R.J., Benson S.A. et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection // AIDS. - 2010. - Vol. 24. - P. 1867-1876.
  31. Malone J.L., Simms T.E., Gray G.C. et al. Sources of variability in repeated T-helper lymphocyte counts from HIV type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important // J. Acquir. Immune Defic. Syndr. - 1990. - Vol. 3. - P. 144-151.
  32. Marimoutou C., Chene G., Mercie P. et al. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998 // JAIDS. - 2001. - Vol. 27. - P. 161-167.
  33. Massanella M., Negredo E., Puig J., Puertas M.C. Raltegravir intensification shows differing effects on CD8 and CD4 T-cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery // AIDS. - 2012. - Vol. 26, N 18. - P. 2285-2293.
  34. Merlini E., Bai F., Bellistrì G.M. et al. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy // PLoS One. - 2011. - Vol. 6, N 4. - P. 18580.
  35. Mezzaroma I., Carlesimo M., Pinter E. et al. Clinical and immanologic response without decrease in virus load in patients with AIDS 24 months of HAART // Clin. Infect. Dis. - 1999. - Vol. 29. - P. 1423-1430.
  36. Mills E.J., Bakanda C., Birungi J. et al. The prognostic value of baseline CD4 cell count beyond 6 months of antiretroviral therapy in HIV positive patients in Uganda // TASO-CAN. - 2012. - Vol. 26, N 11. - P. 1425-1429.
  37. Moore D.M., Hogg R.S., Yip B. et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy // J. Acquir Immune Defic. Syndr. - 2005. - Vol. 40. - P. 288-293.
  38. Motta D., Brianese N., Focà E. et al. Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received // AIDS Res Ther. - 2012. - Vol. 9, N 1. - P. 18.
  39. Napolitano L.A., Schmidt D., Gotway M.D. et al. Growth hormone enhances thymic function in HIV-1 infected adults // J. Clin. Invest. - 2008. - Vol. 118, N 3. - P. 1085-1098.
  40. Negredo E., Molto J., Munoz-Moreno J.A. et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach // Antivir. Ther. - 2004. - Vol. 9. - P. 335-342.
  41. Notermans D.W., Pakker N.G., Hamann D. et al. Immune reconstitution after 2 years of successful potent ART in previously untreated HIV type 1-infected adults // J. Infect. Dis. - 1999. - Vol. 180. - P. 1050-1056.
  42. Okwuraiwe A.P., Audu R.A., Salu O.B. et al. Immunological and virological response to haart in HIV-1 patients co-infected with hepatitis B and C viruses // West Afr. J. Med. - 2012. - Vol. 31, N 2. - P. 124-128.
  43. Piketty C., Weiss L., Thomas F. et al. Long-term clinical outcome of HIV-infected patients with discordant immunologic and virologic responses to a proteas inhibitor-containing regimen // J. Infect. Dis. - 2001. - Vol. 183. - P. 1328-1335.
  44. Piroth L., Duong M., Quantin C. et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? // AIDS. - 1998. - Vol. 12. - P. 381-388.
  45. Powderly W.G., Saag M.S., Chapman S. et al. Predictors of optimal virological response to potent ART // AIDS. - 1999. - Vol. 13. - P. 1873-1880.
  46. Pozniak A.L., Gallant J.E., DeJesus E. et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes a 96-week analysis // JAIDS. - 2006. - Vol. 43. - P. 535-540.
  47. Rachas A., Warszawski J., Le Chenadec J. et al. Does pregnancy affect the early response to cART? // AIDS. - 2013. - Vol. 27, N 3. - P. 357-367.
  48. Robbins G.K., Spritzler J.G., Chan E.S. et al. Incomplete reconstitution of T-cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384 // Clin. Infect. Dis. - 2009. - Vol. 48. - P. 350-361.
  49. Rockstroh I.K. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy // J. Infect. Dis. - 2005. - Vol. 192, N 6. - P. 992-1002.
  50. Sabbatini F., Bandera A., Ferrario G. et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients // PLoS One. - 2010. - Vol. 5, N 11. - Р. 14119.
  51. Shmagel K., Smagel N., Saydakova E. et al. Investigation of mechanisms of immunological inefficiency of antiretroviral therapy in HIV-infected patients / ERA.Net RUS. - Yekaterinburg: Brokerage event, 2011. - P. 34.
  52. Stepanyuk O., Chiang T.S., Dever L.L. et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery // AIDS. - 2009. - Vol. 23. - P. 1911-1913.
  53. Taye S., Lakew M. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: animmunological and clinical chemistry observation, Addis Ababa, Ethiopia // BMC Immunol. - 2013. - Vol. 14. - P. 23.
  54. Teixeira L., Valdez H., McCune J.M. et al. Poor Cd4 T-cell resroration after suppression of HIV-1 replicaition may reflect lower thymic function // AIDS. - 2001. - Vol. 15. - Р. 1749-1756.
  55. Torti C., d’Arminio-Monforte A., Pozniak A.L. et al. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI // BMC Infect. Dis. - 2011. - Vol. 11, N 23. - P. 1471-2334.
  56. Tsiara C.G., Nikolopoulos G.K., Dimou N.L. et al. Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: a meta-analysis // J. Viral. Hepat. - 2013. - Vol. 20, N 10. - P. 715-724.
  57. Viard J.P., Mocroft A., Chiesi A. et al. Influence of age on CD4 cell recovery in HIV-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study // J. Infect. Dis. - 2001. - Vol. 183. - P. 1290-1294.
  58. Wang H., Li Y., Zhang C. et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort // AIDS. - 2012. - Vol. 26, N 14. - P. 1755-1763.

© 2014 Oleynik A.F., Fazylov V.K.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies